Skip to content
Screener

Ironwood Pharmaceuticals IRWD Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
$24.5B-7.3%
Ardelyx logo
ArdelyxARDX
$575.89M+23.4%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$504.61M+187%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$1.04B+44.0%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$2.99B+0.3%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$4.91B+33.0%

Other financials

Income statement

See full
Revenue$113.0M+32.6%
Operating income$79.3M+75.0%
Net income$51.3M+117%
EPS (diluted)$0.31+121%

Balance sheet

See full
Cash & equivalents$79.1M-14.8%
Total debt$11.9M-94.4%
Total equity-$161.8M+47.5%
Total assets$285.1M-16.9%

Cash flow

See full
Operating cash flow$58.3M
CapEx-
Free cash flow$74.6M+390%

Valuation

See full
Market cap$669.22M+395%
Enterprise value$601.96M+135%
P/E5.2×
P/S1.7×+1.3×

Profitability

See full
Gross margin99.2%
Operating margin60.1%+36.4pp
Net margin33.4%+31.1pp
FCF margin24.7%-11.1pp

Returns & leverage

See full
Return on equity29.7%-138pp
Debt / equity-0.5×
Current ratio6.1×+5.2×

Where this comes from

Reported directly by Ironwood Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Ironwood Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091987
Line itemJune 30, 2026December 31, 2025
Stockholders’ deficit:
Preferred stock, $0.001 par value, 75,000,000 shares authorized, no shares issued and outstanding
Class A Common Stock, $0.001 par value, 500,000,000 shares authorized; 165,239,947 shares issued and outstanding as of June 30, 2026 and 163,058,316 shares issued and outstanding as of December 31, 2025165163
Additional paid-in capital1,419,9701,412,780
Accumulated deficit(1,581,654)(1,673,718)
Accumulated other comprehensive loss(324)(1,060)
Total stockholders’ deficit(161,843)(261,835)
Total liabilities and stockholders’ deficit$285,128$396,901

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ironwood Pharmaceuticals's total liabilities & equity?
Ironwood Pharmaceuticals (IRWD) reported total liabilities & equity of $285.13M in Q2 2026.
How has Ironwood Pharmaceuticals's total liabilities & equity changed year-over-year?
Ironwood Pharmaceuticals's total liabilities & equity decreased by 16.9% year-over-year, from $342.95M to $285.13M.
What is the long-term trend for Ironwood Pharmaceuticals's total liabilities & equity?
Over 5 years (2020 to 2025), Ironwood Pharmaceuticals's total liabilities & equity has grown at a -6.6% compound annual growth rate (CAGR), from $559.24M to $396.9M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Ironwood Pharmaceuticals's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude